You are here

Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

Last updated on November 15, 2019

FOR MORE INFORMATION
Study Location
IMIC
Mexico City, Distrito Federal, 06700 Mexico
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Male or female >18 years of age at time of enrollment.

2. The clinical diagnosis of stable plaque psoriasis.

3. Two target plaques of similar severity

1. ≥ 5 cm2 but ≤ 100 cm2 computed by multiplying the greatest diameter of the
plaque by the diameter of the plaque perpendicular to the greatest diameter.

2. Bilaterally located (right/left) plaques on the arms or plaques located on the
upper and lower trunk. Plaques located on the trunk were to be separated by at
least 10 cm and designated by the Investigator as either left/right or
front/back.

3. Target plaque severity score of 2-4 (mild to moderate).

4. Normal or not clinically significant screening laboratory results.

5. Subjects who were willing and able to apply study drug as directed, comply with study
instructions, and commit to all follow-up visits.

6. Subjects who had the ability to understand, agree to and sign the study Informed
Consent Form (ICF) prior to initiation of any protocol related procedures.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Any dermatological conditions that could interfere with clinical evaluations or any
disease state or physical condition which might expose the patient to an unacceptable
risk by study participation

2. Any underlying disease(s) or other dermatological conditions that require the use of
exclusionary topical or systemic therapy (see below)

3. Known sensitivity to any of the components of the study medication

4. Spontaneously improving or rapidly deteriorating psoriatic plaques or
pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis

5. Concomitant use of topical or systemic therapies that might alter the course of
psoriasis

6. Females of child bearing potential. Females must be post-menopausal (based on FSH
levels) or surgically sterile (oophorectomy)

7. Washout periods of:

1. Topical drugs that might alter the course of psoriasis: 2 weeks

2. Oral retinoids: 8 weeks

3. Non-retinoid systemic drugs that might alter the course of psoriasis: 4 weeks

4. PUVA: 4 weeks

5. UVB therapy: 4 weeks

6. Use of emollients/moisturizers on area(s) to be treated: 2 days prior to
baseline visit

8. AIDS or AIDS related illness

9. Concurrent participation in another drug research study or within 30 days of
enrollment

10. Use of lithium or hydroxychloroquine containing products (i.e. Plaquenil)

11. Use of a beta-blocking medication (i.e. propranolol) if the dose has not been
stabilized for at least 3 months

NCT00759161
Pfizer
Completed
Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
NCT03885089
All Genders
0+
Years
Tokyo,
Descriptive Information
Brief Title  ICMJE Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
Official Title  ICMJE A Double-Blind, Randomized Bilateral Study of the Safety and Efficacy of AN2728 Ointment, 5%, Versus Ointment Vehicle in the Treatment of Patients With Plaque Type Psoriasis
Brief SummaryThe purpose of the study is to determine the safety and efficacy of AN2728 Ointment, 5%, compared to Ointment Vehicle in the treatment of plaque type psoriasis.
Detailed DescriptionThis is a multi-center, randomized, double-blind bilateral design. Patients will apply the test articles, AN2728 Ointment, 5%, and Ointment Vehicle twice daily. The assigned study medication will be applied to two comparable treatment targeted plaques identified at baseline. One test article will be applied to one plaque and the other test article to an anatomically distinct plaque. All efficacy evaluations will be measured from only the two plaques identified at the baseline visit.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Psoriasis
Intervention  ICMJE
  • Drug: AN2728
    AN2728 Ointment, 5%, twice daily for 4 weeks
    Other Name: AN2728 Ointment, 5%
  • Drug: AN2728 Ointment Vehicle
    AN2728 Ointment Vehicle, twice daily for 4 weeks.
Study Arms  ICMJE
  • Active Comparator: 1
    AN2728 Ointment, 5%
    Intervention: Drug: AN2728
  • Placebo Comparator: 2
    AN2728 Ointment Vehicle
    Intervention: Drug: AN2728 Ointment Vehicle
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 23, 2008)
35
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE March 2008
Actual Primary Completion DateMarch 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female >18 years of age at time of enrollment.
  2. The clinical diagnosis of stable plaque psoriasis.
  3. Two target plaques of similar severity

    1. ? 5 cm2 but ? 100 cm2 computed by multiplying the greatest diameter of the plaque by the diameter of the plaque perpendicular to the greatest diameter.
    2. Bilaterally located (right/left) plaques on the arms or plaques located on the upper and lower trunk. Plaques located on the trunk were to be separated by at least 10 cm and designated by the Investigator as either left/right or front/back.
    3. Target plaque severity score of 2-4 (mild to moderate).
  4. Normal or not clinically significant screening laboratory results.
  5. Subjects who were willing and able to apply study drug as directed, comply with study instructions, and commit to all follow-up visits.
  6. Subjects who had the ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol related procedures.

Exclusion Criteria:

  1. Any dermatological conditions that could interfere with clinical evaluations or any disease state or physical condition which might expose the patient to an unacceptable risk by study participation
  2. Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see below)
  3. Known sensitivity to any of the components of the study medication
  4. Spontaneously improving or rapidly deteriorating psoriatic plaques or pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis
  5. Concomitant use of topical or systemic therapies that might alter the course of psoriasis
  6. Females of child bearing potential. Females must be post-menopausal (based on FSH levels) or surgically sterile (oophorectomy)
  7. Washout periods of:

    1. Topical drugs that might alter the course of psoriasis: 2 weeks
    2. Oral retinoids: 8 weeks
    3. Non-retinoid systemic drugs that might alter the course of psoriasis: 4 weeks
    4. PUVA: 4 weeks
    5. UVB therapy: 4 weeks
    6. Use of emollients/moisturizers on area(s) to be treated: 2 days prior to baseline visit
  8. AIDS or AIDS related illness
  9. Concurrent participation in another drug research study or within 30 days of enrollment
  10. Use of lithium or hydroxychloroquine containing products (i.e. Plaquenil)
  11. Use of a beta-blocking medication (i.e. propranolol) if the dose has not been stabilized for at least 3 months
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Mexico
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00759161
Other Study ID Numbers  ICMJE AN2728-PSR-201
C3291014 ( Other Identifier: Pfizer )
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateJanuary 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now